baito logo
    navigation?.buttons?.createJob?.text
    Fire
    new
    Indivumed GmbH header
    Indivumed GmbH logo
    #präzisionsonkologie #krebsforschung #bioproben

    Indivumed GmbH

    from Hamburg

    Indivumed is a leading biotech company in precision oncology. It develops data-driven, personalized cancer therapies. Innovation, interdisciplinary collaboration and patient well-being are the focus.

    Visit websiteArrowRight

    Indivumed is a leading biotechnology company based in Hamburg, specializing in precision oncology. Since its founding in 2002, Indivumed has pursued the vision of discovering novel, precise cancer therapies tailored to each patient through patient-centered, data-driven research and development [1][3].

    Core Products and Services
    Indivumed offers a unique combination of highly evaluable clinical biosamples and comprehensive multi-omics data obtained from strictly standardized, rapidly performed tissue sample collections with minimal cold ischemia time. This exceptional quality and diversity of data makes it possible to identify previously hidden therapeutic target structures that drive customized drug development. The company conducts intensive molecular characterization of tumors over many years, which supports the discovery of new, innovative cancer targets and paves the way from small and large molecules to the clinical trial phase (IND) [1][3].

    Mission and Values
    Indivumed sees its main task as advancing precision oncology and creating a world in which a curative therapy is possible for every cancer patient. The patient with his or her individual molecular tumor profiles is always at the center. The corporate culture is characterized by a spirit of innovation, interdisciplinary collaboration and a deep sense of responsibility towards patients and partners [1][3].

    Sustainability Goals and Initiatives
    The company attaches great importance to the quality and integrity of its data in order to achieve sustainable progress in cancer research. Indivumed pursues a patient-oriented approach and relies on close cooperation with international clinical networks in order to jointly accelerate the development of first-generation therapies. The company is also a pioneer in the field of responsible and reproducible research, for example by establishing the minimization of cold ischemia time as a standard in order to preserve the molecular integrity of tissue samples and thus optimize therapeutic insights [1].

    In addition, Indivumed is committed to working in partnership with the pharmaceutical industry and research institutions to make the innovation cycle in oncology more efficient and at the same time enable access to unique data and targeted active ingredients [1][3].

    Current Developments
    In 2023, the company was divided into two units: Indivumed Therapeutics focuses on the data- and AI-driven development of personalized cancer therapies, while the service area was transferred to Crown Bioscience to further strengthen the global provision and analysis of clinical biosamples [4][5].

    Indivumed is thus an innovative driving force for personalized cancer medicine, which is significantly shaping the future of oncology through excellent data quality, interdisciplinary expertise and patient-focused research.

    Sources:

    Edit
    Edit